Revance Therapeutics, Inc.

Form 4

December 19, 2014

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

0.5

January 31, Expires: 2005

**OMB APPROVAL** 

Estimated average

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

Common

Stock

12/17/2014

(Print or Type Responses)

| 1. Name and A Ruegg Curt            | Address of Reporting lis                                                                       | Symb          |                                           | 5. Relationship of Reporting Person(s) to Issuer                                                     |  |  |  |  |  |  |  |  |  |
|-------------------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------|------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|--|
|                                     |                                                                                                |               | ance Therapeutics, Inc. [RVNC             | (Check all applicable)                                                                               |  |  |  |  |  |  |  |  |  |
| (Last)                              | (First) (N                                                                                     | Middle) 3. Da | te of Earliest Transaction                |                                                                                                      |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                | `             | th/Day/Year)                              | Director 10% Owner                                                                                   |  |  |  |  |  |  |  |  |  |
| C/O REVA                            | NCE THERAPEU                                                                                   | JTICS, 12/1   | 7/2014                                    | X Officer (give title Other (specify below)                                                          |  |  |  |  |  |  |  |  |  |
| INC., 7555                          | GATEWAY                                                                                        |               |                                           | EVP R&D and Tech Operations                                                                          |  |  |  |  |  |  |  |  |  |
| BOULEVA                             | RD                                                                                             |               |                                           | ZVI Res and reen operations                                                                          |  |  |  |  |  |  |  |  |  |
|                                     | (Street)                                                                                       | 4. If A       | Amendment, Date Original                  | 6. Individual or Joint/Group Filing(Check                                                            |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                | Filed         | (Month/Day/Year)                          | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person |  |  |  |  |  |  |  |  |  |
| NEWARK,                             | CA 94560                                                                                       |               |                                           |                                                                                                      |  |  |  |  |  |  |  |  |  |
| (City)                              | (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |               |                                           |                                                                                                      |  |  |  |  |  |  |  |  |  |
| 1.Title of                          | 2. Transaction Date                                                                            | 2A. Deemed    | <ol> <li>4. Securities Acquire</li> </ol> | ed 5. Amount of 6. Ownership 7. Nature of                                                            |  |  |  |  |  |  |  |  |  |
| Security (Month/Day/Year) Execution |                                                                                                |               | ` ′ ′ *                                   |                                                                                                      |  |  |  |  |  |  |  |  |  |
| (Instr. 3)                          |                                                                                                | any           | Code (Instr. 3, 4 and 5)                  | Beneficially (D) or Beneficial                                                                       |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                | (Month/Day/Ye | ear) (Instr. 8)                           | Owned Indirect (I) Ownership<br>Following (Instr. 4) (Instr. 4)                                      |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                |               |                                           | Following (Instr. 4) (Instr. 4)<br>Reported                                                          |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                |               | (A)                                       | Transaction(s)                                                                                       |  |  |  |  |  |  |  |  |  |
|                                     |                                                                                                |               | or (D) D                                  | (Instr. 3 and 4)                                                                                     |  |  |  |  |  |  |  |  |  |
| Common                              |                                                                                                |               | Code V Amount (D) Pri                     | ce                                                                                                   |  |  |  |  |  |  |  |  |  |
| Common<br>Stock                     | 12/17/2014                                                                                     |               | M 1,000 A \$2                             | 55 15,106 D                                                                                          |  |  |  |  |  |  |  |  |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $S^{(1)}$ 

1,000

D

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

14,106

D

### Edgar Filing: Revance Therapeutics, Inc. - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5. Number ction Derivative Securities 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |       | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                        |
|-----------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------|-------|----------------------------------------------------------|--------------------|---------------------------------------------------------------------|----------------------------------------|
|                                                     |                                                                       |                                         |                                                             | Code V                                 | (A)                                                                                           | (D)   | Date<br>Exercisable                                      | Expiration<br>Date | Title                                                               | Amount<br>or<br>Number<br>of<br>Shares |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 2.55                                                               | 12/17/2014                              |                                                             | M                                      |                                                                                               | 1,000 | (2)                                                      | 07/20/2020         | Common<br>Stock                                                     | 1,000                                  |

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Ruegg Curtis C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560

**EVP R&D** and Tech Operations

8. l De Sec (In

# **Signatures**

/s/ Gordon Ho, Attorney-in-fact

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- (2) The Option is fully vested as of January 1, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2